Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Carbamazepine in phenobarbital-nonresponders: experience with ten preterm infants
Autore:
Hoppen, T; Elger, CE; Bartmann, P;
Indirizzi:
Univ Bonn, Dept Paediat, Div Neonatol, D-5300 Bonn, Germany Univ Bonn Bonn Germany D-5300 aediat, Div Neonatol, D-5300 Bonn, Germany Univ Bonn, Dept Epileptol, D-5300 Bonn, Germany Univ Bonn Bonn Germany D-5300 Bonn, Dept Epileptol, D-5300 Bonn, Germany
Titolo Testata:
EUROPEAN JOURNAL OF PEDIATRICS
fascicolo: 7, volume: 160, anno: 2001,
pagine: 444 - 447
SICI:
0340-6199(200107)160:7<444:CIPEWT>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEONATAL SEIZURES; PHENYTOIN;
Keywords:
carbamazepine; neonatal seizures; phenobarbital; preterm infants; therapeutic plasma level;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Hoppen, T Community Hosp Kemperhof, Dept Paediat, Koblenzer Str 115-155, D-56065 Koblenz, Germany Community Hosp Kemperhof Koblenzer Str 115-155 Koblenz Germany D-56065
Citazione:
T. Hoppen et al., "Carbamazepine in phenobarbital-nonresponders: experience with ten preterm infants", EUR J PED, 160(7), 2001, pp. 444-447

Abstract

Carbamazepine is a standard anticonvulsant in children and adults. Until now there is only little information available on its use in neonates. We investigated the oral administration of carbamazepine in refractory neonatal seizures treated with phenobarbital. Ten preterm infants (gestational age 23 + 6 - 34 + 6 weeks, birth weight 640 g-3080 g) with neonatal seizures were refractory to a primary therapy with phenobarbital. All patients subsequently received carbamazepine exclusively as a second choice anticonvulsant. A daily dose of 7-23 mg/kg carbamazepine was administered orally in two to three aliquots. All patients reached therapeutic plasma drug levels (3-12 mg/l; 13-50 mu mol/l). In nine out of ten patients (complete group of small preterms with gestational age under 30 weeks and weight less than 1000 g), therapeutic success was excellent. Carbamazepine was continued for 1-5 months. After termination of therapy no further seizures occurred, also on EEG recordings. Finally, no carbamazepine-induced adverse effects were observed. Conclusion This is the first report on the use of carbamazepine in small preterm infants. Carbamazepine may provide a useful and effective oral maintenance therapy in the management of neonatal seizures in these patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 08:37:59